Andrew Dunn

1 day ago | endpoints.news | Andrew Dunn

NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

2 days ago | endpoints.news | Andrew Dunn

Over its 13-year history, Amplify Partners has dabbled in the life sciences as an early backer in companies like Recursion Pharmaceuticals and PicnicHealth. Now, the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

4 days ago | endpoints.news | Andrew Dunn

Richard Saynor’s journey to becoming a self-described patent destroyer was largely by accident. Saynor has been CEO of Sandoz since 2019, but he started his … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

5 days ago | endpts.com | Andrew Dunn

The small biotech Kymera Therapeutics believes it could have a potential oral competitor to the megablockbuster Dupixent. There’s a long road ahead for Kymera’s immunology … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

1 week ago | endpts.com | Andrew Dunn

Novartis won a bidding war against a fellow large drugmaker to acquire Regulus Therapeutics, according to a regulatory filing released Tuesday … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.